CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock	Common Stock	Common Stock Payable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Sub Total	Noncontrolling Interest	Total
Balance at Jul. 31, 2018	$ 4	$ 31,402	$ 2,168,951	$ 368,379,293	$ (409,386,468)	$ 798,422	$ (38,008,396)	$ (5,576,272)	$ (43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	31,402,169
Investment in subsidiary by noncontrolling interest								227,245	227,245
Conversion of preferred series H	$ (3)	$ 28,829		(28,826)
Conversion of preferred series H (in shares)	(63,000)	28,828,953
Conversion of preferred series I	$ (1)	$ 7,584		(7,583)
Conversion of preferred series I (in shares)	(16,590)	7,583,560
Exercise of call option to acquire noncontrolling interest				(6,951,015)			(6,951,015)	5,565,285	(1,385,730)
Issuance of common stock payable		$ 8,495	(1,967,657)	1,959,162			1,967,657		1,967,657
Issuance of common stock payable (in shares)		8,495,924
Issuance of stock options				3,006,203			3,006,203		3,006,203
Issuance of common stock for conversion of debt		$ 2,298		18,404,386			18,406,684		$ 18,406,684
Issuance of common stock for conversion of debt (in shares)		2,297,812							2,297,812
Conversion of debt to equity				$ 15,176,629			$ 15,176,629		$ 15,176,629
Conversion of debt to equity (in shares)
Reduction of derivative liabilities									$ 11,956,044
Purchase of shares in subsidiary									0
Shares issued as debt issuance cost									0
Antigen dividend				$ (1,070,456)			$ (1,070,456)	$ 1,070,456
Issuance of warrants				5,592,244			5,592,244		5,592,244
Acquisition of NCI of Regentys								9,873,553	9,873,553
Acquisition of NCI of Olaregen								11,999,559	11,999,559
Acquisition of Olaregen Series A Preferred Stock				2,520,000			2,520,000	(4,520,000)	(2,000,000)
Reclassification of equity to liability			(201,294)
Extinguishment of derivative liability associated with convertible notes				1,570,174			1,570,174		1,570,174
Currency translation adjustment						(1,206)	(1,206)		(1,206)
Net Income (loss)					(9,341,407)		(9,341,407)	(1,665,387)	(11,006,794)
Balance at Jul. 31, 2019		$ 78,608		408,550,211	(418,727,875)	797,216	(9,301,840)	16,974,439	7,672,599
Balance (in shares) at Jul. 31, 2019		78,608,419
Stock compensation expense				2,069,343			2,069,343		2,069,343
Shares issued for services		$ 790		333,610			334,400		334,400
Shares issued for services (in shares)		789,803
Issuance of shares as a commitment fee in connection with registration statement		$ 1,720		(1,720)
Issuance of shares as a commitment fee in connection with registration statement (in shares)		1,719,901
Issuance of common stock payable		$ 436		935,959			936,395		936,395
Issuance of common stock payable (in shares)		436,121
Issuance of common stock for conversion of debt									$ 5,348,847
Issuance of common stock for conversion of debt (in shares)									11,914,545
Conversion of debt to equity		$ 11,914		5,336,933			5,348,847		$ 5,348,847
Conversion of debt to equity (in shares)		11,914,545
Issuance of common stock for acquisitions		$ 960		1,150,992			1,151,952		1,151,952
Issuance of common stock for acquisitions (in shares)		960,000
Reduction of derivative liabilities				4,593,765			4,593,765		4,593,765
Cancellation of shares		$ (20,376)		20,376
Cancellation of shares (in shares)		(20,375,900)
Purchase of shares in subsidiary		$ 7,856		6,571,811			6,579,667	(6,579,667)
Purchase of shares in subsidiary (in shares)		7,855,912
Shares issued as debt issuance cost		$ 343		150,887			151,230		151,230
Shares issued as debt issuance cost (in shares)		343,000
Settlement of subsidiary's liability with stock				32,212			32,212		32,212
Currency translation adjustment						(16,920)	(16,920)		(16,920)
Net Income (loss)					(33,335,030)		(33,335,030)	(897,063)	(34,232,093)
Balance at Jul. 31, 2020		$ 82,251		$ 429,744,379	$ (452,062,905)	$ 780,296	$ (21,455,979)	$ 9,497,709	$ (11,958,270)
Balance (in shares) at Jul. 31, 2020		82,251,801